Tentative Outline

Anti-Cancer Agents in Medicinal Chemistry

Guest Editor(s): Bingjin Li, PhD and Runhua Liu, PhD;

TITLE: Immunotherapeutic approaches in cancer treatment

Aims & Scope:
To date, advanced cancer in most cases remains incurable and potentially lethal, underscoring the urgent need for alternative strategies for cancer therapy. Cancer immunotherapy is a treatment of cancer by inducing, enhancing an immune response, attempting to stimulate the immune system to reject and destroy tumors, which is of great interest for clinical application. Thus, in this special issue, we discuss the rationale and recent trial results of certain immunotherapeutic agents in cancer therapy. These specialists will review cancer immunotherapeutic approaches and give a comprehensive overview of the anti-cancer effects of specific signaling pathways inhibitors and other agents on multiple human malignancies, particularly in advanced cancer cases. These reviews might provide a new insight into the immunotherapeutic strategies for clinical cancer therapy.

Key words: cancer progression, prognosis, immunotherapy, small molecule inhibitor, drug development, multimodal approach.

Subtopics of interest include, but are NOT limited to:
1. Reprogram of tumor metabolism and cancer immunotherapy (Dr Yuan Shen, Kochi University Medical School, Japan.)
2. The effects of mTOR pathway inhibitors on human prostate cancer (Dr Lizhong Wang, University of Alabama at Birmingham, U.S.A)
3. The application of phage display in cancer immunotherapy (Dr Yichun Wang, University of Pittsburgh, U.S.A)
4. PD-1/PD-L1 immune checkpoint and breast cancer immunotherapy (Dr Runhua Liu, University of Alabama at Birmingham, U.S.A)
5. Immunologic checkpoint blockade in the treatment of advanced cancer. (Dr Guanquan Li, Jilin University, China)
6. Evolving roles for targeting of CTLA-4 in cancer immunotherapy (Dr Guangxin Zhang, University of Alabama at Birmingham, U.S.A)
7. Oncolytic virus-based immunotherapeutic agents for use against colon cancer (Dr Bingjin Li, Jilin University, China)
8. Car-T cell immunotherapy of cancer (Dr Bingjin Li, Jilin University, China)
9. Immuno-enhancement effects of natural herbal compound on human cancer (Dr Ranji Cui, Jilin University, China)
10. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in cancer therapy (Dr Runhua Liu, University of Alabama at Birmingham,)

Schedule:
Manuscript submission deadline: 30 June 2016
Peer Review Due: 30 July 2016
Revision Due: 30 August 2016
Notification of acceptance by the Guest Editor: 30 September 2016
Final manuscripts due: 30 October 2016
Tentative Publication Date: May 2019